Attenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant use
Natalie Gukasyan, Roland R. Griffiths, David B. Yaden, Denis Antoine, Sandeep M. Nayak
Journal of Psychopharmacology June 8, 2023 DOI: 10.1177/02698811231179910 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Retrospective survey Peer reviewed |
|---|---|
| Sample size | 2,153 |
| Population | Individuals with use of psilocybin mushrooms with an antidepressant or within 2 years of discontinuing an antidepressant |
| Intervention | psilocybin mushrooms |
| Topics | Psilocybin Serotonin |
| Keywords | Antidepressant Fluoxetine Discontinuation Bupropion Serotonin reuptake inhibitor Pharmacology Sertraline |
| Citations | 60 |
| Key findings | SSRI/SNRIs appear to weaken psilocybin drug effects relative to bupropion, and this dampening may last up to three months following antidepressant discontinuation. |
Abstract
Background: Psilocybin is being studied for depression, but little is known about how it interacts with common antidepressants. Limited data suggest that psilocybin’s effects may be diminished by serotonergic antidepressants acutely and even after a medication washout period.
Aims: To learn the extent to which antidepressants may diminish the effects of psilocybin-containing mushrooms both concurrently and after discontinuation of antidepressants.
Methods: Online retrospective survey of individuals with use of psilocybin mushrooms (1) with an antidepressant and/or (2) within 2 years of discontinuing an antidepressant. Participants who took mushrooms with an antidepressant and either took the same dose pre-antidepressant or took the same dose with other people not on antidepressant reported the strength of drug effects relative to their expectation. Participants who took mushrooms following discontinuation of an antidepressant also reported the presence of weakened effects.
Results: In reports ( n = 611) of taking mushrooms with an antidepressant, probabilities [95% CI] of weaker than expected drug effects were 0.47 [0.41–0.54] (selective serotonergic reuptake inhibitors, SSRIs), 0.55 [0.44–0.67] (serotonin norepinephrine reuptake inhibitors, SNRIs) and 0.29 [0.2–0.39] (bupropion). Following SSRI/SNRI discontinuation ( n = 1,542 reports), the probability of reduced drug effects was not significantly different from the earliest post-discontinuation timepoint (within 1 week) until 3–6 months, probability = 0.3 [0.20–0.46], p = 0.001. A sensitivity analysis found that removing responses involving fluoxetine, which has an especially long half-life, did not significantly alter this result.
Conclusions: SSRI/SNRIs appear to weaken psilocybin drug effects relative to a non-serotonergic antidepressant. This dampening effect may last as long as 3 months following antidepressant discontinuation.
Comparable studies
Other cross-sectional and survey studies on psilocybin, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences Individuals who had consumed psilocybin mushrooms and experienced a psychologically... | 2016 | Cross-sectional survey | n = 1,993 |
| The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms Internet survey respondents reporting challenging experiences with psilocybin | 2016 | Questionnaire development and validation | |
| Psychedelics and Mental Health: A Population Study Adult population in the United States | 2013 | Cross-sectional survey | n = 130,152 |
| Cessation and reduction in alcohol consumption and misuse after psychedelic use Individuals with prior alcohol use disorder who reported cessation or reduction in... | 2019 | Cross-sectional survey | n = 343 |
| Patterns of simultaneous polysubstance use in drug using university students Drug-using university students | 2006 | Cross-sectional survey | n = 149 |
Citations in the library
Cited by 54
- Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication. Neuropsychopharmacology September 1, 2023
- Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: results from a prospective, longitudinal survey Frontiers in Psychiatry September 19, 2023
- Drug–drug interactions involving classic psychedelics: A systematic review Journal of Psychopharmacology November 20, 2023
- Interactions between classic psychedelics and serotonergic antidepressants: Effects on the acute psychedelic subjective experience, well-being and depressive symptoms from a prospective survey study. Journal of Psychopharmacology January 27, 2024
- Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression Journal of Psychopharmacology March 22, 2024
and 49 more in the library
Cites 17
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder JAMA Psychiatry November 4, 2020
- Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine November 3, 2022
- Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology November 8, 2017
- Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later Journal of Psychopharmacology May 30, 2008
and 12 more in the library